Tachyphylaxis to the action of topically applied corticosteroids

Vivier, Anthony du

doi:10.1001/archderm.111.5.581

Cited by 72 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using double immunostaining for KLK6 and the proliferation marker BrdU, we found that even though KLK6 protein was expressed in non-proliferating suprabasal keratinocytes, KLK6 + cells were frequently adjacent to BrdU + cells in the basal layer (Figure 1e). We found previously that most of proliferating keratinocytes in the skin chronically treated with glucocorticoids were localized in the IFE, but not in the bulge stem cell niche [8]. We confirmed this earlier finding here (Figures 1e and 3a).…”

Section: Resultssupporting

confidence: 93%

“…In line with our previous observations [8], the overall burst of proliferation during tachyphylaxis occurred in IFE, and this coincided with the prevalent KLK6 expression in the same epidermal compartment. Remarkably, KLK6 expression was frequently seen in suprabasal keratinocytes adjacent to FA-resistant proliferating basal keratinocytes.…”

Section: Discussionsupporting

confidence: 92%

“…We and others previously showed that after two weeks of topical steroid treatment, interfollicular keratinocytes in mouse skin lost sensitivity to glucocorticoid-induced anti-proliferative effects, and that keratinocyte proliferation that was drastically reduced at the beginning of treatment (10-15% of control level) returned to, or exceeded, the control level later after chronic treatment [10,11]. As discussed below, steroid tachyphylaxis in patients is also well documented, even though in some cases it may reflect irregular steroid use [8,9,12–14]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids

et al. 2016

View full text Add to dashboard Cite

One of the major adverse effects of topical glucocorticoids is cutaneous atrophy often followed by development of resistance to steroids (tachyphylaxis). Previously we showed that after two weeks, interfollicular mouse keratinocytes acquired resistance to anti-proliferative effects of glucocorticoid fluocinolone acetonide (FA). One of the top genes activated by FA during tachyphylaxis was Klk6 encoding kallikrein-related peptidase 6, known to enhance keratinocyte proliferation. KLK6 was also strongly induced by chronic glucocorticoids in human skin. Double immunostaining showed that KLK6+ keratinocytes, localized in suprabasal layer of mouse skin, were frequently adjacent to proliferating 5-bromo-2'-deoxyuridine-positive basal keratinocytes. We used KLK6 knockout (KO) mice to evaluate KLK6 role in skin regeneration after steroid-induced atrophy. KLK6 KOs had thinner epidermis and decreased keratinocyte proliferation. The keratinocytes in wild type and KLK6 KO epidermis were equally sensitive to acute anti-proliferative effect of FA. However, the development of proliferative resistance during chronic treatment was reduced in KO epidermis. This was not due to the changes in glucocorticoid receptor (GR) expression or function as GR protein level and induction of GR-target genes were similar in wild type and KLK6 KO skin. Overall, these results suggest a novel mechanism of epidermal regeneration after glucocorticoid-induced atrophy via KLK6 activation.

show abstract

Section: Resultssupporting

confidence: 93%

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The common and known clinical perception of tachyphylaxis may also be significantly related to issues of compliance outside the study group, or to vessels flare unrelated to therapy. Du Vivier and Stoughton, in 1975, were the first describing the persistence and recurrence of psoriasis in patients who were previously treated with topical corticosteroids with a successful result [121]. The question remains if this is a truly clinical entity or if it is just due to a nonadherence to the topical regimen.…”

Section: Commentsmentioning

confidence: 99%

Mechanisms of Action of Topical Corticosteroids in Psoriasis

Uva¹,

Miguel²,

Pinheiro³

et al. 2012

International Journal of Endocrinology

167

128

View full text Add to dashboard Cite

Psoriasis is a lifelong, chronic, and immune-mediated systemic disease, which affects approximately 1–3% of the Caucasian population. The different presentations of psoriasis require different approaches to treatment and appropriate prescriptions according to disease severity. The use of topical therapy remains a key component of the management of almost all psoriasis patients, and while mild disease is commonly treated only with topical agents, the use of topical therapy as adjuvant therapy in moderate-to-severe disease may also be helpful. This paper focuses on the cutaneous mechanisms of action of corticosteroids and on the currently available topical treatments, taking into account adverse effects, bioavailability, new combination treatments, and strategies to improve the safety of corticosteroids. It is established that the treatment choice should be tailored to match the individual patient's needs and his/her expectations, prescribing to each patient the most suitable vehicle.

show abstract

“…Du Vivier and Stoughton16 reported tachyphylaxis related to TCS, in an experiment measuring vasoconstriction after consecutive application, for 4 days, of a potent TCS. The effect was improved by the cessation of TCS over the following several days.…”

Section: Three Problems From the Viewpoint Of Preventing Tsa Or Rbss mentioning

confidence: 99%

Topical steroid addiction in atopic dermatitis

Fukaya¹,

Satô²,

Sato³

et al. 2014

DHPS

View full text Add to dashboard Cite

The American Academy of Dermatology published a new guideline regarding topical therapy in atopic dermatitis in May 2014. Although topical steroid addiction or red burning skin syndrome had been mentioned as possible side effects of topical steroids in a 2006 review article in the Journal of the American Academy of Dermatology, no statement was made regarding this illness in the new guidelines. This suggests that there are still controversies regarding this illness. Here, we describe the clinical features of topical steroid addiction or red burning skin syndrome, based on the treatment of many cases of the illness. Because there have been few articles in the medical literature regarding this illness, the description in this article will be of some benefit to better understand the illness and to spur discussion regarding topical steroid addiction or red burning skin syndrome.

show abstract

Tachyphylaxis to the action of topically applied corticosteroids

Cited by 72 publications

References 0 publications

Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids

Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids

Mechanisms of Action of Topical Corticosteroids in Psoriasis

Topical steroid addiction in atopic dermatitis

Contact Info

Product

Resources

About